The Health Quality & Safety Commission New Zealand is running an 18-month formative collaborative to reduce opioid-related harm in hospitals.
The collaborative aim is to reduce opioid-related harm by 25 percent in district health board* (DHB) hospital’s participating areas, and build capability in medication safety and quality improvement methodology.
The collaborative began in September 2014 and ends in April 2016.
Opioids were chosen for the collaborative because of the associated harm identified in incident reports and a global trigger tool study done in three DHBs (1). The Institute for Healthcare Improvement’s (IHI) collaborative methodology (2) is being used and the IHI is providing external advice.
Participation in the collaborative is voluntary. All 20 DHBs and one private hospital are taking part. Only 18 of the multidisciplinary teams are actively testing interventions using plan-do-study-act cycles. The other three teams are engaged and learning the methodology. Teams include a consumer whenever possible.
Team members in individual hospitals are not funded. The Commission’s national collaborative team provides leadership, guidance and support through visits, phone calls and webinars. The Commission hosted four regional learning events as part of the initial engagement approach. Three national learning sessions when teams come together to learn and share have been hosted and up to three team members from each DHB were funded to attend.
Teams have used local findings to choose the opioid-related harm and the target ward(s) to work on. Most are aiming to reduce harm from opioid-related constipation, but there are teams focusing on respiratory depression, uncontrolled pain and nausea and vomiting.
It is anticipated that a bundle of evidence-based interventions will be identified by the end of the collaborative for implementation in any hospital area.
The formative collaborative is being independently evaluated. This has been ongoing and learnings are considered throughout.
Further information and learning session materials are available on the Commission’s website.
* A district health board is responsible for providing or funding the provision of health services in their district. Disability support services and some health services are funded and purchased nationally by the Ministry of Health.
- Seddon ME, Jackson A, Cameron C et al. The Adverse Drug Event Collaborative: a joint venture to measure medication-related patient harm. NZMJ 2013; 126 (1368): 9-20.
- Institute for Healthcare Improvement. The Breakthrough Series: Institute for Healthcare Improvement’s (IHI) Collaborative Model for Achieving Breakthrough Improvement. IHI Innovation Series white paper. 2003. Read on...
14 December 2015 - The International Medication Safety Network (IMSN) has issued a position statement that calls for greater worldwide attention to the problem of unsafe design of vaccine packaging and labelling. The statement calls on healthcare professionals, pharmaceutical companies, technology vendors, professional organizations, and regulatory/standard-setting organizations to help improve vaccine safety and efficacy.
The IMSN statement provides recommendations, including:
- Packaging that minimizes the need to prepare individual doses, provides unit dose according to the mode of administration, and redesigned vials (where vials are still used) to accommodate larger labels.
- Labelling that uses larger fonts for better readability; adoption of World Health Organization Vaccine Presentation and Packaging Advisory Group (WHO VPPAG) expiration dates standard; provision of peel-off labels to facilitate syringe labelling; and improved differentiation of pediatric and adult formulations.
- For vaccines provided with diluents or two component vaccines:
-- Packaging that forces proper mixing of the diluent or of the two components of the vaccine; for example a two-chambered syringe or vial. If not feasible, vials of vaccine and diluent or second component should be packaged together without prejudice of storage requirements.
-- Provide clear instructions in or on the label for mixing components of vaccines requiring
reconstitution. Display directions and warning to administer contents of both vials together on the front label of each carton, vial, and vial cap. The label of diluents must primarily identify them as such and make it clear they are not the actual vaccine. For example, “DILUENT for preparing” followed by name of vaccine. Place warning on diluents that they are not the actual product.
- Healthcare authorities and regulators should promote safer labelling and packaging of vaccines and make available recommendations to healthcare providers for safer vaccination practices.
Vaccine manufacturers are strongly encouraged to revise packaging and labelling as specified, with particular attention on vaccines with diluents or two-component vaccines. For a complete copy of the position statement, click here.
The European Medicines Agency (EMA) has published a good practice guide on medication errors to improve the reporting, evaluation and prevention of medication errors by regulatory authorities and pharmaceutical industry throughout the European Union (EU). This EMA good practice guide on medication errors complements the guideline on good pharmacovigilance practices (GVP) and other existing guidelines published by the EMA. It consists of two parts:
- the first part details how suspected adverse reactions that are caused by medication errors should be recorded, coded, reported and assessed. EMA expects this will improve reporting and learning from medication errors for the benefit of public health.
- the second part of the guide clarifies key principles of risk management planning by the EMA in relation to medication errors.
In parallel, EMA has launched a webpage highlighting measures recommended by the Agency to prevent medication errors for specific medicines. Although this information is also available in the European public assessment reports (EPAR) of these medicines, the purpose of these documents is to increase awareness of the additional measures recommended by EMA in order to ensure that a specific medicine is used correctly and to reduce the risk of medication errors. On November 27, 2015, EMA made following documents available on this new webpage:
- Questions and answers on recommendations to prevent administration errors with Velcade (bortezomib) (20/01/2012)
- European Medicines Agency recommends measures to ensure safe and effective use of Strensiq (26/06/2015)
- Guidance on prevention of medication errors with high-strength insulins (27/11/2015)
- Guidance on prevention of medication errors with diabetes medicines containing insulin and a non-insulin active substance (27/11/2015)
- Compliance card to be given to patients using Farydak - Compliance card will ensure correct use and avoid medication errors (27/11/2015)
EMA efforts to communicate on any additional measure decided upon at EU level to prevent medication errors are welcome. However, as stated since a long time by the International Medication Safety Network (IMSN) members, education and information do not significantly reduce errors on their own, because they rely on memory. In particular, IMSN recommends that regulations for medicines naming, labelling and packaging in all countries should be strengthened to: require safer design and field testing before release for use; incorporate human factors theory; promote safer use in practice.
In October 2013, the International Medication Safety Network issued recommendations to regulators, pharmaceutical industry and healthcare providers as part of a comprehensive, worldwide solution to the problem of unsafe medicines naming, labelling and packaging. Download PDF
During the 2013 Paris Conference on safer naming, labelling and packaging of medicines, Dr. Michael Cohen, chairperson of IMSN, proposed that regulators and other stakeholders join IMSN at a summit to address this global threat to patient safety. This summit is expected to be held during fall 2015.